Dragonboat Biopharmaceutical Company Limited

This Phase II study tests a drug called BC006 in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The trial first checks safety in a small group, then randomly assigns patients to receive BC006 or a placebo every tw…